A Strong Q2FY27 For KIMS | Confident Of EBITDA Improvement Over The Next Few Quarters, Says Company
CNBC-TV18 · 05 Nov 2026 · 6 min
Management interview of Krishna Institute of Medical Sciences Ltd (KIMS), with 11 key numbers discussed.
- Bhaskar Rao, Chairman & MD, Krishna Institute of Medical Sciences Ltd
KIMS reports no material impact so far from drug price capping discussions, as oncology accounts for 7-8% of revenue. Of 11 newly opened units, all except one are now EBITDA positive. Management expects EBITDA margins to expand from 19.2% in H1 to 23-25% by the end of FY27 and 26-27% in FY28. Debt reduced from Rs 3,100 cr to Rs 2,100 cr following the June QIP, with net debt projected at Rs 2,300-2,400 cr by year-end. Over the next two to three years, the company plans to add 1,000 beds with a capex of Rs 1,000 cr, targeting 20%+ annual revenue growth.